Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
CombiMatrix Corporation
Type
Public
Traded as NASDAQ: CBMX
Industry Genetic testing
Headquarters Irvine, CA, United States
Key people
Mark McDonough (CEO), Scott Burell (CFO), Weslie Tyson (CMO)
Products CombiSNP Array Prenatal, CombiSNP for Miscarriage Analysis, CombiSNP for Pediatric and Postnatal Analysis
Services SNP Miscarriage Analysis for Recurrent Pregnancy Loss, Prenatal Analysis, Pediatric Analysis
Website www.combimatrix.com

CombiMatrix Corp. (NASDAQ: CBMX) CombiMatrix is a clinical diagnostic laboratory specializing in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric diagnostics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray analysis, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making.

In 2012 CombiMatrix shifted its focus from providing oncology genetic testing to developmental testing. Their focus is cytogenomic miscarriage analysis, prenatal analysis and postnatal/pediatric analysis.

CombiMatrix uses the CombiSNP Array as their technology platform. SNP stands for Single nucleotide polymorphism probes. These probes allow for increased precision and greater diagnostic yield. This array contains more than 845,000 SNP markers covering both coding and non-coding human genome sequences. The median spatial resolution between probes is 1 Kb within gene rich regions and 5 Kb outside of gene-rich regions.

Investment goal date:
Dividends reinvested
CombiMatrix Corporation CBMX report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-21
--
--
Q3 2017
2017-11-03
--
--
Q2 2017
2017-08-03
-0.1300
-0.1300
Q1 2017
2017-05-04
-0.1900
-0.1900
Q4 2016
2017-02-22
-0.2200
-0.2200
Q3 2016
2016-11-02
-0.3800
-0.3800
Q2 2016
2016-08-03
-0.8900
-0.8900
Q1 2016
2016-05-04
-1.7300
-3.6300
Q4 2015
2016-02-17
-1.8200
-1.9500
Q3 2015
2015-11-04
-1.8000
-1.9500
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ACADIAN ASSET MANAGEMENT LLC
6293
Bank of New York Mellon Corp
29678
BARD ASSOCIATES INC
76890
BlackRock Fund Advisors
8019
BlackRock Inc.
9591
BRIDGEWAY CAPITAL MANAGEMENT INC
39800
DIMENSIONAL FUND ADVISORS LP
19192
ESSEX INVESTMENT MANAGEMENT CO LLC
13314
FNY Managed Accounts LLC
5000
KCG Holdings, Inc.
51608
MORGAN STANLEY
66
PANAGORA ASSET MANAGEMENT INC
32017
THOMPSON DAVIS & CO., INC.
1000
Tower Research Capital LLC (TRC)
1900
Vanguard Group, Inc
25185
Major Shareholders
Name Relationship
Total Shares
Holding stocks
ABELES JOHN H
0.0800% (9119)
CBMX /
AKIN THOMAS B
1.0700% (118418)
CBMX / DX / IMH /
ANDERSON BROOKE P
0.2900% (32348)
CBMX /
HOFFMAN ROBERT
0.0700% (7409)
ARNA / CBMX / HRTX / TELK /
KUMAR AMIT
0.8500% (94398)
ASTI / CBMX / ITUS /
JESSUP R JUDD
0.4000% (43702)
CBMX / CRVL /
JONES JEREMY M
0.2700% (30023)
ASGN / CBMX /
Burell Scott R
0.0400% (4332)
CBMX /
Gottlieb Scott
0.0400% (4804)
CBMX /
McGowan Mark
2.0900% (230918)
CBMX / PRXI /
FORCHE DANIEL R
0.1000% (11399)
CBMX /
Ding Richard
0.1600% (17495)
CBMX /
Hockett Richard Jr
0.0100% (1000)
CBMX /
McDonough Mark D
0.4100% (45269)
CBMX /
Tyson Robert Weslie
0.0700% (7500)
CBMX /
White Lale
0.0700% (8000)
CBMX /
% ()